Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 169 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Development, Human Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

NCT01606709
View directory record Official record
Conditions
Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
Interventions
GnRH agonist, hCG
Drug
Lead sponsor
UConn Health
Other
Eligibility
21 Years to 33 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 22, 2026, 5:54 PM EDT
Terminated Phase 4 Interventional Results available

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

NCT00328926
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 22, 2026, 5:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skeletal Muscle Effects of GH in Boys

NCT04020913
View directory record Official record
Conditions
Growth Hormone Deficiency, Idiopathic Short Stature
Interventions
Somatropin injection
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
6 Years to 11 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 22, 2026, 5:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)

NCT05518188
View directory record Official record
Conditions
Spasticity, Muscle, Microcephaly, Intellectual Deficiency, Growth Retardation, SPG50, Spastic Paraplegia
Interventions
MELPIDA
Biological
Lead sponsor
Elpida Therapeutics SPC
Industry
Eligibility
4 Months to 10 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 5:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Natural Sugars in Breast Milk on Healthy Infant Growth and Development

NCT04434027
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 59 Years · Female only
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 22, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Growth Hormone and Chromosome 18q- and Abnormal Growth

NCT00134420
View directory record Official record
Conditions
Loss of Chromosome 18q, Growth Hormone Deficiency
Interventions
Nutropin AQ, Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, Neuropsychological Testing
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 22, 2026, 5:54 PM EDT
Completed No phase listed Observational

Effects of HIV on the Development and Function of Bone Marrow Cells

NCT00001243
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 5:54 PM EDT
Terminated No phase listed Observational

Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma

NCT00767936
View directory record Official record
Conditions
Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver, Hepatobiliary Cancers
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 22, 2026, 5:54 PM EDT
Completed No phase listed Observational

A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])

NCT05101902
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Pre-Screening
Other
Lead sponsor
Adrenas Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

NCT02418767
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
MOD-4023, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 22, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)

NCT04662151
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
AT-100, Air-sham
Biological · Procedure
Lead sponsor
Airway Therapeutics, Inc.
Industry
Eligibility
0 Minutes to 96 Hours
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 22, 2026, 5:54 PM EDT
Terminated Phase 4 Interventional Results available

Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus

NCT00260208
View directory record Official record
Conditions
Liver Transplant, Hepatitis C
Interventions
Cyclosporine A, Tacrolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 22, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency

NCT00489294
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Syntropin
Drug
Lead sponsor
Phage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Oct 22, 2026, 5:54 PM EDT
Not listed Phase 1 Interventional

Development of Human Laboratory Study Model of Cocaine Relapse Prevention. - 1

NCT00040066
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Cocaine (IV)
Procedure
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Los Angeles, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 22, 2026, 5:54 PM EDT
Completed Phase 1 Interventional

In Vitro Human Embryo Culture System

NCT00985218
View directory record Official record
Conditions
Infertility
Interventions
SMART System, Culture dish
Device
Lead sponsor
Incept BioSystems, Inc.
Industry
Eligibility
21 Years to 35 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
San Francisco, California • Clearwater, Florida • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Oct 22, 2026, 5:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Pilot Testing of a PHCI for Emergency Department Patients Who Decline Rapid HIV/ HCV Screening

NCT04137094
View directory record Official record
Conditions
Hiv, Hepatitis C
Interventions
Persuasive Health Communication Intervention
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 22, 2026, 5:54 PM EDT
Terminated Phase 3 Interventional

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

NCT03145831
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Somavaratan
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 22, 2026, 5:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

The Discriminative Effects of Tramadol in Humans

NCT00499746
View directory record Official record
Conditions
Opioid Abuse, Opioid Addiction, Stimulant Abuse, Stimulant Addiction
Interventions
tramadol, placebo, Hydromorphone, Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Months to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 22, 2026, 5:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

NCT02980341
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Patritumab Deruxtecan
Drug
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Newnan, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 22, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

NCT04615273
View directory record Official record
Conditions
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin, Placebo, Somatropin
Drug · Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 80 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 5:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study

NCT04774081
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
24h Continuous glucose monitoring and urinary C-peptide collection
Device
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 22, 2026, 5:54 PM EDT
Recruiting No phase listed Observational

A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders

NCT06092346
View directory record Official record
Conditions
AMPD3, OMIM*102772, AMP Deaminase Deficiency, AK1, OMIM *103000, Adenylate Kinase Deficiency, AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency, TPMT, OMIM *187680, Thoipurines, Poor Metabolism of, IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11, APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency, HPRT1, OMIM *308000 Lesch-Nyhan Disease, XDH, OMIM *607633, Xanthinuria Type 1, SLC2A9, OMIM *606142 Hypouricemia, SLC22A12, OMIM *607096 Hypouricemia, PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease, PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity, AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia, ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35, ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency, PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency, ADA2, OMIM *607575,Sneddon Syndrome; VAIHS, CAD, *1140120, Developmental and Epileptic Encephalopathy, UPB1, OMIM *606673, Beta-ureidopropionase Deficiency, DPYS, OMIM *613326, Dihydropyrimidinase Deficiency, DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency, DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis), UMPS, OMIM *613891, Orotic Aciduria, NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency, UNG, OMIM *191525, Hyper-IgM Syndrome 5, AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2, Purine-Pyrimidine Metabolism, Metabolic Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 100 Years
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2099
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 22, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Imaging Study of Adults With Autism Spectrum Disorders

NCT01093768
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Oxytocin, Vasopressin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 5:54 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine

NCT02597738
View directory record Official record
Conditions
Lung Cancer, Head and Neck Cancer
Interventions
Fresh tissue biopsy, Blood/Urine Sample Collection
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 99 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 22, 2026, 5:54 PM EDT